New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention

For decades, lowering LDL cholesterol meant one thing: a statin. This review maps how much that has changed — and the growing menu for patients statins can’t get to goal.

The authors run through the modern lipid-lowering toolkit beyond statins: PCSK9 monoclonal antibodies (roughly 60% LDL reduction), bempedoic acid (about 18% alone, ~38% with ezetimibe, and useful in statin intolerance because it isn’t active in muscle), inclisiran (about 50% with a twice-yearly injection that sidesteps daily adherence), and evinacumab for the rare homozygous familial hypercholesterolemia. The throughline is that the field now has options at every rung of the ladder.

The practical takeaway is escalation rather than resignation: when a patient remains above target or can’t tolerate statins, add ezetimibe, a PCSK9 inhibitor, bempedoic acid, or inclisiran per guidelines and access. The resistance is cost and a statin-only mindset among payers and some clinicians.

We rate the evidence moderate: a 70-reference narrative review synthesizing trial and regulatory data, with outcomes data still pending for some agents and one author disclosing industry advisory ties. Its clinical significance is higher — it addresses a real, common gap for high-risk patients — bounded mainly by cost, access, and the maturity of outcome evidence for the newest drugs.